Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis
Nucleoside analogues are recommended as antiviral treatments for patients with hepatitis B virus (HBV)-associated liver failure. Clinical data comparing entecavir (ETV) and lamivudine (LAM) are inconsistent in this setting. To compare the efficacy and safety of ETV and LAM in patients with chronic h...
Gespeichert in:
Veröffentlicht in: | Hepatitis monthly 2014-11, Vol.14 (11), p.e19164-e19164 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e19164 |
---|---|
container_issue | 11 |
container_start_page | e19164 |
container_title | Hepatitis monthly |
container_volume | 14 |
creator | Zhang, Xiaoguo An, Yong Jiang, Xuemei Xu, Minling Xu, Linlin Chen, Shijun Xi, Yaguang |
description | Nucleoside analogues are recommended as antiviral treatments for patients with hepatitis B virus (HBV)-associated liver failure. Clinical data comparing entecavir (ETV) and lamivudine (LAM) are inconsistent in this setting.
To compare the efficacy and safety of ETV and LAM in patients with chronic hepatitis B (CHB)-associated liver failure.
A literature search was performed on articles published until January 2014 on therapy with ETV and LAM for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was the primary efficacy measure, while total bilirubin (TBIL), prothrombin activity (PTA) changes and HBV DNA negative change rates were secondary efficacy measures. A quantitative meta-analysis was performed to compare the efficacy of the two drugs. Safety of ETV and LAM was observed.
Four randomized controlled trials and nine retrospective cohort studies comprising a total of 1549 patients were selected. Overall analysis revealed comparable survival rates between patients received ETV and those received LAM (4 weeks: RR = 1.03, 95%CI [0.89, 1.18], P = 0.73; 8 weeks: RR = 0.98, 95% CI [0.85, 1.14], P = 0.84; 12 weeks: RR = 0.98, 95% CI [0.90, 1.08], P = 0.70; 24 weeks: RR = 1.02, 95% CI [0.94, 1.10], P = 0.66). After 24 weeks of treatment, patients treated with ETV had a significantly lower TBIL levels (MD = -37.34, 95% CI [-63.57, -11.11], P = 0.005), higher PTA levels (MD = 11.10, 95% CI [2.47, 19.73], P = 0.01) and higher HBV DNA negative rates (RR = 2.76, 95% CI [1.69, 4.51], P < 0.0001) than those treated with LAM. In addition, no drug related adverse effects were observed in the two treatment groups.
ETV and LAM treatments had similar effects to improve 24 weeks survival rate of patients with CHB-associated liver failure, but ETV was associated with greater clinical improvement. Both drugs were tolerated well during the treatment. It is suggested to perform further studies to verify the results. |
doi_str_mv | 10.5812/hepatmon.19164 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4286714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652384619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1ffc42e6078b4c4362969c728e3eccb1cac9f31ca9e140ceb2616eed5db910bd3</originalsourceid><addsrcrecordid>eNpVUU1v1DAUtBCIloUrR-Qjlyz-imNzQKJV-ZBW6qVI3KwX54UYJfFiO4v23xPabdWe5klv3szoDSFvOdvWhosPA-6hTHHecsu1ekbOeSPrSipmnp9mruTPM_Iq59-M1YY14iU5E3VtTWP0OclXc0EPh5DoAVNeMt3BFA5LF2akZcAE-yPtY6KrTcC5ZPo3lIH6IcU5eHprH0rI9KKCnKMPULCjY1jFaA9hXBJ-pEAnLFDBDOMxh_yavOhhzPjmhBvy48vVzeW3anf99fvl513lpWWl4n3vlUDNGtMqr6QWVlvfCIMSvW-5B297uYJFrpjHVmiuEbu6ay1nbSc35NOd7n5pJ-z8Gj_B6PYpTJCOLkJwTzdzGNyveHBKGN2sf9uQ9yeBFP8smIubQvY4jjBjXLLjuhbSKM3tSt3eUX2KOSfsH2w4c_-bcvdNudum1oN3j8M90O-rkf8AVZ2V7Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652384619</pqid></control><display><type>article</type><title>Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zhang, Xiaoguo ; An, Yong ; Jiang, Xuemei ; Xu, Minling ; Xu, Linlin ; Chen, Shijun ; Xi, Yaguang</creator><creatorcontrib>Zhang, Xiaoguo ; An, Yong ; Jiang, Xuemei ; Xu, Minling ; Xu, Linlin ; Chen, Shijun ; Xi, Yaguang</creatorcontrib><description>Nucleoside analogues are recommended as antiviral treatments for patients with hepatitis B virus (HBV)-associated liver failure. Clinical data comparing entecavir (ETV) and lamivudine (LAM) are inconsistent in this setting.
To compare the efficacy and safety of ETV and LAM in patients with chronic hepatitis B (CHB)-associated liver failure.
A literature search was performed on articles published until January 2014 on therapy with ETV and LAM for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was the primary efficacy measure, while total bilirubin (TBIL), prothrombin activity (PTA) changes and HBV DNA negative change rates were secondary efficacy measures. A quantitative meta-analysis was performed to compare the efficacy of the two drugs. Safety of ETV and LAM was observed.
Four randomized controlled trials and nine retrospective cohort studies comprising a total of 1549 patients were selected. Overall analysis revealed comparable survival rates between patients received ETV and those received LAM (4 weeks: RR = 1.03, 95%CI [0.89, 1.18], P = 0.73; 8 weeks: RR = 0.98, 95% CI [0.85, 1.14], P = 0.84; 12 weeks: RR = 0.98, 95% CI [0.90, 1.08], P = 0.70; 24 weeks: RR = 1.02, 95% CI [0.94, 1.10], P = 0.66). After 24 weeks of treatment, patients treated with ETV had a significantly lower TBIL levels (MD = -37.34, 95% CI [-63.57, -11.11], P = 0.005), higher PTA levels (MD = 11.10, 95% CI [2.47, 19.73], P = 0.01) and higher HBV DNA negative rates (RR = 2.76, 95% CI [1.69, 4.51], P < 0.0001) than those treated with LAM. In addition, no drug related adverse effects were observed in the two treatment groups.
ETV and LAM treatments had similar effects to improve 24 weeks survival rate of patients with CHB-associated liver failure, but ETV was associated with greater clinical improvement. Both drugs were tolerated well during the treatment. It is suggested to perform further studies to verify the results.</description><identifier>ISSN: 1735-143X</identifier><identifier>EISSN: 1735-3408</identifier><identifier>DOI: 10.5812/hepatmon.19164</identifier><identifier>PMID: 25598786</identifier><language>eng</language><publisher>Iran: Kowsar</publisher><ispartof>Hepatitis monthly, 2014-11, Vol.14 (11), p.e19164-e19164</ispartof><rights>Copyright © 2014, Kowsar Corp. 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1ffc42e6078b4c4362969c728e3eccb1cac9f31ca9e140ceb2616eed5db910bd3</citedby><cites>FETCH-LOGICAL-c390t-1ffc42e6078b4c4362969c728e3eccb1cac9f31ca9e140ceb2616eed5db910bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286714/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286714/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25598786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiaoguo</creatorcontrib><creatorcontrib>An, Yong</creatorcontrib><creatorcontrib>Jiang, Xuemei</creatorcontrib><creatorcontrib>Xu, Minling</creatorcontrib><creatorcontrib>Xu, Linlin</creatorcontrib><creatorcontrib>Chen, Shijun</creatorcontrib><creatorcontrib>Xi, Yaguang</creatorcontrib><title>Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis</title><title>Hepatitis monthly</title><addtitle>Hepat Mon</addtitle><description>Nucleoside analogues are recommended as antiviral treatments for patients with hepatitis B virus (HBV)-associated liver failure. Clinical data comparing entecavir (ETV) and lamivudine (LAM) are inconsistent in this setting.
To compare the efficacy and safety of ETV and LAM in patients with chronic hepatitis B (CHB)-associated liver failure.
A literature search was performed on articles published until January 2014 on therapy with ETV and LAM for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was the primary efficacy measure, while total bilirubin (TBIL), prothrombin activity (PTA) changes and HBV DNA negative change rates were secondary efficacy measures. A quantitative meta-analysis was performed to compare the efficacy of the two drugs. Safety of ETV and LAM was observed.
Four randomized controlled trials and nine retrospective cohort studies comprising a total of 1549 patients were selected. Overall analysis revealed comparable survival rates between patients received ETV and those received LAM (4 weeks: RR = 1.03, 95%CI [0.89, 1.18], P = 0.73; 8 weeks: RR = 0.98, 95% CI [0.85, 1.14], P = 0.84; 12 weeks: RR = 0.98, 95% CI [0.90, 1.08], P = 0.70; 24 weeks: RR = 1.02, 95% CI [0.94, 1.10], P = 0.66). After 24 weeks of treatment, patients treated with ETV had a significantly lower TBIL levels (MD = -37.34, 95% CI [-63.57, -11.11], P = 0.005), higher PTA levels (MD = 11.10, 95% CI [2.47, 19.73], P = 0.01) and higher HBV DNA negative rates (RR = 2.76, 95% CI [1.69, 4.51], P < 0.0001) than those treated with LAM. In addition, no drug related adverse effects were observed in the two treatment groups.
ETV and LAM treatments had similar effects to improve 24 weeks survival rate of patients with CHB-associated liver failure, but ETV was associated with greater clinical improvement. Both drugs were tolerated well during the treatment. It is suggested to perform further studies to verify the results.</description><issn>1735-143X</issn><issn>1735-3408</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVUU1v1DAUtBCIloUrR-Qjlyz-imNzQKJV-ZBW6qVI3KwX54UYJfFiO4v23xPabdWe5klv3szoDSFvOdvWhosPA-6hTHHecsu1ekbOeSPrSipmnp9mruTPM_Iq59-M1YY14iU5E3VtTWP0OclXc0EPh5DoAVNeMt3BFA5LF2akZcAE-yPtY6KrTcC5ZPo3lIH6IcU5eHprH0rI9KKCnKMPULCjY1jFaA9hXBJ-pEAnLFDBDOMxh_yavOhhzPjmhBvy48vVzeW3anf99fvl513lpWWl4n3vlUDNGtMqr6QWVlvfCIMSvW-5B297uYJFrpjHVmiuEbu6ay1nbSc35NOd7n5pJ-z8Gj_B6PYpTJCOLkJwTzdzGNyveHBKGN2sf9uQ9yeBFP8smIubQvY4jjBjXLLjuhbSKM3tSt3eUX2KOSfsH2w4c_-bcvdNudum1oN3j8M90O-rkf8AVZ2V7Q</recordid><startdate>20141111</startdate><enddate>20141111</enddate><creator>Zhang, Xiaoguo</creator><creator>An, Yong</creator><creator>Jiang, Xuemei</creator><creator>Xu, Minling</creator><creator>Xu, Linlin</creator><creator>Chen, Shijun</creator><creator>Xi, Yaguang</creator><general>Kowsar</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141111</creationdate><title>Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis</title><author>Zhang, Xiaoguo ; An, Yong ; Jiang, Xuemei ; Xu, Minling ; Xu, Linlin ; Chen, Shijun ; Xi, Yaguang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1ffc42e6078b4c4362969c728e3eccb1cac9f31ca9e140ceb2616eed5db910bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiaoguo</creatorcontrib><creatorcontrib>An, Yong</creatorcontrib><creatorcontrib>Jiang, Xuemei</creatorcontrib><creatorcontrib>Xu, Minling</creatorcontrib><creatorcontrib>Xu, Linlin</creatorcontrib><creatorcontrib>Chen, Shijun</creatorcontrib><creatorcontrib>Xi, Yaguang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatitis monthly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiaoguo</au><au>An, Yong</au><au>Jiang, Xuemei</au><au>Xu, Minling</au><au>Xu, Linlin</au><au>Chen, Shijun</au><au>Xi, Yaguang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis</atitle><jtitle>Hepatitis monthly</jtitle><addtitle>Hepat Mon</addtitle><date>2014-11-11</date><risdate>2014</risdate><volume>14</volume><issue>11</issue><spage>e19164</spage><epage>e19164</epage><pages>e19164-e19164</pages><issn>1735-143X</issn><eissn>1735-3408</eissn><abstract>Nucleoside analogues are recommended as antiviral treatments for patients with hepatitis B virus (HBV)-associated liver failure. Clinical data comparing entecavir (ETV) and lamivudine (LAM) are inconsistent in this setting.
To compare the efficacy and safety of ETV and LAM in patients with chronic hepatitis B (CHB)-associated liver failure.
A literature search was performed on articles published until January 2014 on therapy with ETV and LAM for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was the primary efficacy measure, while total bilirubin (TBIL), prothrombin activity (PTA) changes and HBV DNA negative change rates were secondary efficacy measures. A quantitative meta-analysis was performed to compare the efficacy of the two drugs. Safety of ETV and LAM was observed.
Four randomized controlled trials and nine retrospective cohort studies comprising a total of 1549 patients were selected. Overall analysis revealed comparable survival rates between patients received ETV and those received LAM (4 weeks: RR = 1.03, 95%CI [0.89, 1.18], P = 0.73; 8 weeks: RR = 0.98, 95% CI [0.85, 1.14], P = 0.84; 12 weeks: RR = 0.98, 95% CI [0.90, 1.08], P = 0.70; 24 weeks: RR = 1.02, 95% CI [0.94, 1.10], P = 0.66). After 24 weeks of treatment, patients treated with ETV had a significantly lower TBIL levels (MD = -37.34, 95% CI [-63.57, -11.11], P = 0.005), higher PTA levels (MD = 11.10, 95% CI [2.47, 19.73], P = 0.01) and higher HBV DNA negative rates (RR = 2.76, 95% CI [1.69, 4.51], P < 0.0001) than those treated with LAM. In addition, no drug related adverse effects were observed in the two treatment groups.
ETV and LAM treatments had similar effects to improve 24 weeks survival rate of patients with CHB-associated liver failure, but ETV was associated with greater clinical improvement. Both drugs were tolerated well during the treatment. It is suggested to perform further studies to verify the results.</abstract><cop>Iran</cop><pub>Kowsar</pub><pmid>25598786</pmid><doi>10.5812/hepatmon.19164</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1735-143X |
ispartof | Hepatitis monthly, 2014-11, Vol.14 (11), p.e19164-e19164 |
issn | 1735-143X 1735-3408 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4286714 |
source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
title | Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A33%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Entecavir%20versus%20Lamivudine%20therapy%20for%20patients%20with%20chronic%20hepatitis%20B-associated%20liver%20failure:%20a%20meta-analysis&rft.jtitle=Hepatitis%20monthly&rft.au=Zhang,%20Xiaoguo&rft.date=2014-11-11&rft.volume=14&rft.issue=11&rft.spage=e19164&rft.epage=e19164&rft.pages=e19164-e19164&rft.issn=1735-143X&rft.eissn=1735-3408&rft_id=info:doi/10.5812/hepatmon.19164&rft_dat=%3Cproquest_pubme%3E1652384619%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652384619&rft_id=info:pmid/25598786&rfr_iscdi=true |